CD274 and cancer: However, cancer cells can produce certain key modifications through genetic or epigenetic changes to escape the surveillance of immune system and limit the efficacy of immunotherapy, including down-regulation of their major histocompatibility complex I (MHC I) antigen and up-regulation of PD-L1 inhibitory molecules (Vesely et al., 2011).